-
Your selected country is
India
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).
Product Notices
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- CF™ is a trademark of Biotium, Inc.
- BD Horizon Brilliant Ultraviolet 615 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
Companion Products
KS1/4 antigen (Ag), defined by the KS1/4 antibody (KS1/4), is expressed in many epithelial-derived carcinomas and normal epithelial cell surfaces. The cDNA encoding KS1/4 has been isolated and contains an open reading frame of 314 amino acids including a putative signal sequence. KS1/4 Ag migrates as three glycosylated polypeptides with molecular masses of 35, 40 and 42 kDa. The 40 and 42 kDa species are similar proteins and appear to differ only by their degree of N-linked glycosylation. The 35 kDa species results from proteolytic cleavages of the larger molecular weight proteins. KS1/4 was first described as a monoclonal antibody which recognized a lung adenocarcinoma associated antigen. In oncolytic drug targeting studies, KS1/4 suppressed the growth of human lung tumor xenografts in athymic nude mice. Subsequent studies showed that KS1/4 reacts with a variety of tumor tissues including colon, breast, ovarian, and pancreas. It also recognizes normal epithelium including colon, stomach, small intestine, liver, kidney, lung, pancreas, skin and ovary. These results suggest that KS1/4 Ag represents an epithelial cell/epithelial-derived carcinoma marker. KS1/4 recognizes a 40 - 42 kDa antigen expressed on the cell surfaces of a variety of epithelial tumors and normal epithelial cell types. KS1/4 also recognizes a 35 kDa proteolytic fragment. UCLA-P3 cells derived from a human adenocarcinoma of the lung were used as immunogen.
The antibody was conjugated to BD Horizon BUV615 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome with an Ex Max near 350 nm and an Em Max near 615 nm. BD Horizon Brilliant BUV615 can be excited by the ultraviolet laser (355 nm) and detected with a 610/20 filter and a 595 nm LP. Due to the excitation of the acceptor dye by the blue/yellow-green laser line, there may be significant spillover into channels detecting PE-CF594 like emissions (eg, 610/20-nm filter).
Development References (5)
-
Bumol TF, Marder P, DeHerdt SV, Borowitz MJ, Apelgren LD. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. Hybridoma. 1988; 7(4):407-415. (Clone-specific: Flow cytometry, Immunohistochemistry). View Reference
-
Perez MS, Walker LE. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Immunol. 1989; 142(10):3662-3667. (Clone-specific: Immunoprecipitation). View Reference
-
Spearman ME, Goodwin RM, Apelgren LD, Bumol TF. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J Pharmacol Exp Ther. 1987; 241(2):695-703. (Biology). View Reference
-
Varki NM, Reisfeld RA, Walker LE. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 1984; 44(2):681-687. (Immunogen: Immunofluorescence, Immunohistochemistry, Immunoprecipitation). View Reference
-
Varki NM, Reisfeld RA, Walker LE. Effect of monoclonal antibody-drug conjugates in teh in vivody growth of h uman tumors established in nude mice. In: Reisfeld R, Sell S, ed. Monoclonal Antibodies in Cancer Therapy, vol. 27. New York: Alan R Liss, Inc; 195:207.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.